What question did this study set out to answer?

The aim was to evaluate the efficacy of upadacitinib in patients with head and neck atopic dermatitis.

May 26, 2026Dermatology and Therapy0 citationsOpen Access

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region

KEK Eyerich PMP. Mendes-Bastos GHGregor Holzer

Key Points

The aim was to evaluate the efficacy of upadacitinib in patients with head and neck atopic dermatitis.
Post hoc analysis of Measure Up 1 and Measure Up 2 trials (NCT03569293, NCT03607422).
Patients received either upadacitinib 15 mg, 30 mg, or placebo.
Efficacy was assessed at week 16 using EASI scores and patient-reported outcomes.
Upadacitinib 15 mg achieved EASI ≤ 0.3 in 46.8%, EASI 90 in 41.9%, and EASI 100 in 29.1%; corresponding rates for 30 mg were 58.0%, 56.5%, and 42.4%.
Placebo group achieved EASI ≤ 0.3 in 13.5%, EASI 90 in 11.5%, and EASI 100 in 9.0%.
Median percentage reduction in EASI at week 16 was 87.8% for 15 mg and 96.3% for 30 mg.

Abstract

INTRODUCTION: Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422). METHODS: Patients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index EASI) received upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 almost clear, EASI 90 near-complete clearance, EASI 100 complete clearance, and patient-reported outcomes PROs) through week 16. RESULTS: At week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15 mg (46.8%, 41.9%, 29.1%) and upadacitinib 30 mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15 mg and 96.3% for upadacitinib 30 mg. CONCLUSIONS: Upadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement. TRIAL REGISTRATION: ClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).

问 AI

Bookmark

View Full Paper